¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.
Fiche publication
Date publication
février 2016
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COCHET Alexandre
Tous les auteurs :
Groheux D, Cochet A, Humbert O, Alberini JL, Hindié E, Mankoff D
Lien Pubmed
Résumé
Many studies have pointed out the role of (18)F-FDG PET/CT (or (18)F-FDG PET) in patients with clinical stage III or II breast cancer. (18)F-FDG PET/CT might advantageously replace other staging procedures, such as bone scanning and possibly contrast-enhanced CT of the thorax or abdomen-pelvis. We discuss the findings, locoregional or distant, that can be expected in different categories of breast cancer and their impact on prognosis and management. We also discuss the role of (18)F-FDG PET/CT in restaging and how (18)F-FDG PET/CT compares with conventional techniques in restaging for patients with suspected disease recurrence. We conclude with some recommendations for clinical practice and future research.
Mots clés
Breast Neoplasms, diagnostic imaging, Female, Fluorodeoxyglucose F18, Humans, Multimodal Imaging, Neoplasm Staging, methods, Positron-Emission Tomography, methods, Prognosis, Radiopharmaceuticals, Tomography, X-Ray Computed
Référence
J. Nucl. Med.. 2016 Feb;57 Suppl 1:17S-26S